CBP/EP300-BRD inhibition redirects tumour-associated MDSCs from a suppressive to an inflammatory phenotype through STAT pathway-related gene downregulation and ARG1 and iNOS inhibition, thus limiting tumour growth in a model of colon carcinoma [84]. This evidence concerns the gene NOS2 and neoplasm.